ストックスクリーナーアプリを入手
20.66
3.59%
-0.77
プレマーケット:
20.67
0.01
+0.05%
前日終値:
$21.43
開ける：
$21.1
24時間の取引高:
2.21M
Relative Volume:
1.16
時価総額：
$2.34B
収益：
$70.92M
当期純損益:
$-342.21M
株価収益率:
-5.4883
EPS:
-3.7644
ネットキャッシュフロー:
$-304.30M
1週間 パフォーマンス:
-5.79%
1か月 パフォーマンス:
-13.99%
6か月 パフォーマンス:
-24.02%
1年 パフォーマンス:
+5.95%
1日の値動き範囲:
$20.22
$21.25
1週間の範囲:
$20.22
$22.40
52週間の値動き範囲:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Compare VRDN vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
20.66 | 2.34B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 繰り返されました | Wedbush | Outperform |
| 2025-12-03 | 開始されました | William Blair | Outperform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 開始されました | TD Cowen | Buy |
| 2024-09-11 | 繰り返されました | Needham | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-05-09 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 開始されました | BTIG Research | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-05-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-04-17 | 開始されました | Wells Fargo | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2022-12-19 | 開始されました | Cowen | Outperform |
| 2022-12-19 | 開始されました | Needham | Buy |
| 2022-12-16 | 開始されました | Credit Suisse | Outperform |
| 2022-12-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-23 | 開始されました | B. Riley Securities | Buy |
| 2021-11-18 | 開始されました | SVB Leerink | Outperform |
| 2021-10-12 | 開始されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Viridian Therapeutics Inc (VRDN) 最新ニュース
(VRDN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says - finance.yahoo.com
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38 - Moomoo
RBC Capital maintains Outperform rating on Viridian Therapeutics, $38 price target - TradingView
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
Viridian Therapeutics shifts focus to launch ex... - Pluang
Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN) - Seeking Alpha
Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - theglobeandmail.com
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Viridian Therapeutics Inc (VRDN:UW): Stock Price, Quote and News - BNN Bloomberg
260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP - MarketBeat
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing - GuruFocus
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares By Investing.com - Investing.com Canada
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares - Investing.com
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares - MarketBeat
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan
Viridian (VRDN) Latest Quarter: Reported Results Sit Close to Expectations; Session Move: The Stock Ends Down 1.21% in Latest TradingEarnings Preview - Vinanet
Steven Cohen’s Point72 discloses Viridian stake (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers - Sahm
ETFs Investing in Viridian Therapeutics, Inc. Stocks - TradingView
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026 - Stock Titan
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - Stock Titan
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan
Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan
Viridian Therapeutics, Inc. (1S1) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Trading the Move, Not the Narrative: (VRDN) Edition - news.stocktradersdaily.com
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside - TradingView
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial - theglobeandmail.com
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22% - simplywall.st
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Viridian Therapeutics (VRDN) Rises 2.84% as Biotech Stock Approaches Key Resistance at $24.9Volatility Smile - careplusvn.com
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates - 富途牛牛
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
VRDN Maintained by RBC Capital -- Price Target Raised to $36.00 - GuruFocus
Viridian Therapeutics Inc (VRDN) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):